A new landmark study from Sweden, published in The BMJ, confirmed the long-term durability of the Human Papillomavirus (HPV) vaccine. This research provides the strongest evidence of “sustained protection” of the vaccine against invasive cervical cancer, with no signs of waning of immunity.
These findings are expected to bolster global public health strategies aimed at eliminating cervical cancer through high-coverage routine vaccination programmes.
The Challenge of Long-Term Immunity
Persistent infection with high-risk HPV types is the primary contributor to invasive cervical cancer. While HPV vaccination is a cornerstone of global efforts to eliminate this disease for nearly two decades, scientific evidence regarding its long-term efficacy has remained relatively limited.
A key question for clinicians and policymakers has been whether the protection offered in adolescence remains robust as women move into their 30s and 40s—when cervical cancer risk increases.
To address this, researchers utilised Sweden’s comprehensive nationwide registries to track the health outcomes of nearly one million women. The study evaluated the risk of invasive cervical cancer in those who received the quadrivalent HPV vaccine compared to those who remained unvaccinated.
Study Methodology and Data Scope
The research team followed 926,362 girls and women born between 1985 and 2001 over an 18-year period (2006–2023). Participants were followed up to a maximum age of 38, rendering a robust statistical foundation to evaluate the vaccine’s real-world performance over two decades.
The participants were categorised into four distinct cohorts based on the nature of the vaccination programme available to them:
- Opportunistic Cohort (born 1985–88): Self-funded vaccination
- Subsidised Cohort (born 1989–92): Government-subsidised initiatives
- Catch-up Cohort (born 1993–98): Parallel programmes for school-aged pupils
- School-based Cohort (born 1999–2001): Routine, free-of-charge vaccination delivered via school health infrastructure
The analysis accounted for various contributing factors, including:
- County of residence and parental income
- Level of parental education
- Mother’s country of birth
- Previous history of non-cervical cancers or high-grade lesions
Key Findings: The Importance of Early Vaccination
Of the total participants, 40% received at least one dose of the quadrivalent vaccine. During the follow-up period, 930 incident cases of invasive cervical cancer were identified. Among these, 833 occurred in unvaccinated women, compared to just 97 in the vaccinated group.
The data showed a stark difference between that vaccinated and the unvaccinated groups. Further, the age at which a person is vaccinated plays a critical role in the level of protection achieved.
Those vaccinated before the 17 years of age experienced the most significant benefits.
Comparative Risk Reduction of Invasive Cervical Cancer:
| Group | Risk Reduction (%) | Long-term Stability (13–15 Years) |
| Vaccinated < Age 17 | 79% Lower Risk | 77% Lower Risk |
| Vaccinated > Age 17 | 37% Lower Risk | 77% Lower Risk* |
Evidence of Sustained Protection
The results showed that early vaccinated conferred a remarkably stable protection against invasive cervical cancer.
Crucially, there was no indication of waning or attenuation of immunity over time.
For girls vaccinated between the ages of 10 and 16, the incidence rate ratios (IRRs) remained consistently low throughout the follow-up period. The IRR was 0.24 at 7–9 years post-vaccination and 0.23 at 13–15 years post-vaccination.
For those vaccinated later in life (age 17 years or older), the benefit became more apparent over a longer horizon. While no significant protection was observed during the first nine years—likely due to pre-existing HPV exposure at the time of vaccination—a significant risk reduction was recorded during years 10–12 (IRR 0.54) and 13–15 (IRR 0.23), after vaccination.
At 15 years post-vaccination, the risk of developing invasive cervical cancer remained approximately 77% lower than in the unvaccinated population.
This attests that the vaccine’s prophylactic benefits remain clinically vital even when administered during adulthood.
A Population-Level Decline
Beyond individual protection, the study highlights a dramatic shift in cervical cancer rates across different generations. Women born between 1985 and 1988, who reached adulthood before the vaccination programmes, saw cervical cancer incidence rates of approximately 250 cases per 100,000 – by age 38.
In contrast, for the cohort born between 1999 and 2001, who had the highest access to routine immunisation, the rate plummeted to 4 cases per 100,000 – by age 24.
The findings reaffirm the success of organised, national immunisation strategies. The school-based cohort achieved the highest vaccine uptake (76.2%) and the youngest median age at vaccination (12.2 years). This group showed a 72% lower risk of cervical cancer compared to the opportunistic cohort.
The clinical impact of this research is two-fold:
- The data reinforce current global strategies that prioritise vaccination at a young age through school-based programmes.
- The delayed risk reduction in older cohorts highlights the need for extended follow-up (longer than a decade) to accurately evaluate the effectiveness of the the vaccination initiatives.
Global Implications for Cancer Elimination
The 18-year follow-up provides the first clinical confirmation that the quadrivalent HPV vaccine offers durable, long-term protection against invasive cervical cancer with no loss of efficacy over time. These vaccination programmes significantly reduced the chronic low-grade infection that causes cervical malignancy and represent a pivotal advancement in public health.
The results provide robust evidence to support the World Health Organization’s goal of eliminating cervical cancer as a public health threat.
By achieving high coverage in younger populations, healthcare systems can effectively neutralise one of the most common causes of cancer-related deaths in women.
These findings confer healthcare professionals and policymakers the evidence needed to continue advocating for high vaccine coverage as a primary tool for the global elimination of cervical cancer. As nations continue to refine their immunisation strategies, the Swedish data serve as a powerful reminder that early intervention provides a lifetime of security. HPV vaccination can eliminate cervical cancer risk for future generations.
Keywords: HPV vaccination, cervical cancer prevention, sustained protection, quadrivalent HPV vaccine, The BMJ study, clinical impact, school-based vaccination, invasive cervical cancer, routine immunisation programmes, public health data.
Suggested Reads:
https://www.bmj.com/content/392/bmj-2025-087326
chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/http://press.psprings.co.uk/bmj/february/cervicalcancer.pdf
chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/http://press.psprings.co.uk/AMSlabels.pdf
